Cargando…
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
OBJECTIVE: To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, and Scopus to 1 December 2020. ELIGI...
Autores principales: | Conforti, Fabio, Pala, Laura, Sala, Isabella, Oriecuia, Chiara, De Pas, Tommaso, Specchia, Claudia, Graffeo, Rossella, Pagan, Eleonora, Queirolo, Paola, Pennacchioli, Elisabetta, Colleoni, Marco, Viale, Giuseppe, Bagnardi, Vincenzo, Gelber, Richard D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689398/ https://www.ncbi.nlm.nih.gov/pubmed/34933868 http://dx.doi.org/10.1136/bmj-2021-066381 |
Ejemplares similares
-
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis
por: Pala, Laura, et al.
Publicado: (2022) -
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
por: Conforti, Fabio, et al.
Publicado: (2019) -
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023) -
EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Conforti, Fabio, et al.
Publicado: (2020) -
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations()
por: Conforti, Fabio, et al.
Publicado: (2021)